# STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

Study · id `cardio:ct-nct02943590` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02943590](<https://clinicaltrials.gov/study/NCT02943590>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02943590

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

## Technical summary

Registry record NCT02943590. Randomized; double masking; primary purpose treatment. Start 2017-01-13 (actual); primary completion 2022-09-16 (actual). Results posted on 2023-12-18.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (enrolled count; ClinicalTrials.gov record NCT02943590, source copy `cardio:ctgov-nct02943590-2025-05-15`, retrieved 2026-10-26)
- Started: 2017-01-13 (actual) (ClinicalTrials.gov record NCT02943590, source copy `cardio:ctgov-nct02943590-2025-05-15`, retrieved 2026-10-26)
- Primary completion: 2022-09-16 (actual) (ClinicalTrials.gov record NCT02943590, source copy `cardio:ctgov-nct02943590-2025-05-15`, retrieved 2026-10-26)
- Completion: 2023-10-11 (actual) (ClinicalTrials.gov record NCT02943590, source copy `cardio:ctgov-nct02943590-2025-05-15`, retrieved 2026-10-26)
- Results first posted: 2023-12-18 (ClinicalTrials.gov record NCT02943590, source copy `cardio:ctgov-nct02943590-2025-05-15`, retrieved 2026-10-26)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02943590, source copy `cardio:ctgov-nct02943590-2025-05-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02943590-2025-05-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)
- Condition: Heart Failure
- Intervention (Drug): Placebo
- Intervention (Drug): Atorvastatin
- Lead sponsor: Massachusetts General Hospital
- Lead sponsor class: OTHER
- Collaborator: Dana-Farber Cancer Institute
- Collaborator class: OTHER
- Collaborator: Brigham and Women's Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Massachusetts General Hospital (`cardio:org-massachusetts-general-hospital`)
- Registry lists this organization as a collaborator: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial (`cardio:pubmed-37552303`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP (`cardio:pubmed-38380861`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atorvastatin and left atrial function during anthracycline-based chemotherapy (`cardio:pubmed-40876541`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial (`cardio:pubmed-41205202`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Atorvastatin and left ventricular strain during anthracycline-based chemotherapy (`cardio:pubmed-41875954`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 592807cd6c27bc7ee7b472a5c18b3056eec730ce0b9f7c1a36e16adbc3cecdd0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
